Form 4: Cingulate Inc. Executive Raul R. Silva Acquires Stock Options

Raul R. Silva, EVP and CSO of Cingulate Inc., reports the acquisition of stock options.

Summary

• Raul R. Silva, the EVP and CSO of Cingulate Inc., filed a Form 4.
• The form reports the acquisition of 1,000 stock options on September 30, 2024, with an exercise price of $5.04.
• These options were granted according to the terms of Dr. Silva's employment agreement.
• The options are exercisable from September 30, 2024, and expire on September 30, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The grant of options is generally viewed as a positive incentive, but it's not a major event.

Positives

• The grant of stock options to a key executive like the CSO can be seen as an incentive to align their interests with the company's long-term success.

Management Comments

• The option was granted pursuant to the terms of Dr. Silva's Employment Agreement, as amended.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options to their executives as part of their overall compensation strategy.
• The specific terms of these grants, such as the exercise price, vesting schedule, and expiration date, can vary depending on the company's size, performance, and industry practices.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting ownership if the options are exercised in the future.
• It incentivizes the CSO to work towards increasing shareholder value.

Key Dates

Keywords

Form 4, Stock Options, Cingulate Inc., Insider Trading, Beneficial Ownership, Raul R. Silva, CING, EVP, CSO